DOP2011000130A - 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 - Google Patents
1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6Info
- Publication number
- DOP2011000130A DOP2011000130A DO2011000130A DO2011000130A DOP2011000130A DO P2011000130 A DOP2011000130 A DO P2011000130A DO 2011000130 A DO2011000130 A DO 2011000130A DO 2011000130 A DO2011000130 A DO 2011000130A DO P2011000130 A DOP2011000130 A DO P2011000130A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- disorders
- disease
- schizophrenia
- cognitive
- deficit
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- MAYQIFVKVAUMPD-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-methyl-4-piperazin-1-ylbenzimidazole Chemical compound CC1=NC2=C(N3CCNCC3)C=CC=C2N1S(=O)(=O)C1=CC=CC=C1 MAYQIFVKVAUMPD-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000014679 binge eating disease Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11329608P | 2008-11-11 | 2008-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000130A true DOP2011000130A (es) | 2017-04-30 |
Family
ID=41404503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000130A DOP2011000130A (es) | 2008-11-11 | 2011-05-10 | 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 |
Country Status (41)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4958785B2 (ja) * | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 |
| CA2580844A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
| TW200626148A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| BRPI0515489A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase |
| CN104557726B (zh) * | 2013-10-19 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| EP3166924B1 (en) | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| WO2017052394A1 (en) | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
| EP3530651A1 (en) * | 2018-02-21 | 2019-08-28 | Adamed sp. z o.o. | Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists |
| WO2021021951A1 (en) | 2019-07-29 | 2021-02-04 | Vanderbilt University | Wdr5-myc inhibitors |
| IL297448A (en) * | 2020-04-22 | 2022-12-01 | Recurium Ip Holdings Llc | Preparation of an selective estrogen receptor degrader |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0773942A1 (en) | 1994-07-26 | 1997-05-21 | Pfizer Inc. | 4-indole derivatives as serotonin agonists and antagonists |
| US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| JP2002511097A (ja) | 1997-07-11 | 2002-04-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| DK0930302T3 (da) | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
| US6251893B1 (en) | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| JP4346243B2 (ja) | 1998-08-10 | 2009-10-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プロトン・ポンプ・インヒビターのプロドラッグ |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
| BR0114552A (pt) | 2000-10-20 | 2003-07-01 | Biovitrum Ab | N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia |
| SE0003810D0 (sv) * | 2000-10-20 | 2000-10-20 | Pharmacia Ab | Novel compounds their use and preparations |
| CN1222511C (zh) * | 2000-11-02 | 2005-10-12 | 惠氏公司 | 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚 |
| US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物 |
| BR0210411A (pt) * | 2001-06-15 | 2004-08-17 | Hoffmann La Roche | Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6 |
| WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| JP4768265B2 (ja) | 2002-10-15 | 2011-09-07 | シンタ ファーマシューティカルズ コーポレーション | 新規化合物 |
| TWI380816B (zh) | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑 |
| BRPI0512674A (pt) | 2004-07-28 | 2007-09-25 | Irm Llc | compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
-
2009
- 2009-10-11 UA UAA201105862A patent/UA100192C2/uk unknown
- 2009-11-10 EP EP09752080A patent/EP2285784B1/en active Active
- 2009-11-10 NZ NZ592563A patent/NZ592563A/xx not_active IP Right Cessation
- 2009-11-10 MY MYPI2011001681A patent/MY156324A/en unknown
- 2009-11-10 ME MEP-2011-75A patent/ME01129B/me unknown
- 2009-11-10 SI SI200930293T patent/SI2285784T1/sl unknown
- 2009-11-10 HR HRP20120561AT patent/HRP20120561T1/hr unknown
- 2009-11-10 AU AU2009314221A patent/AU2009314221B2/en not_active Ceased
- 2009-11-10 AP AP2011005664A patent/AP2814A/xx active
- 2009-11-10 PL PL09752080T patent/PL2285784T3/pl unknown
- 2009-11-10 PE PE2011001015A patent/PE20120026A1/es not_active Application Discontinuation
- 2009-11-10 MX MX2011004996A patent/MX2011004996A/es active IP Right Grant
- 2009-11-10 GE GEAP200912221A patent/GEP20135805B/en unknown
- 2009-11-10 EA EA201100696A patent/EA018369B1/ru not_active IP Right Cessation
- 2009-11-10 BR BRPI0920682A patent/BRPI0920682A2/pt not_active IP Right Cessation
- 2009-11-10 KR KR1020117010610A patent/KR101323417B1/ko not_active Expired - Fee Related
- 2009-11-10 CA CA2740262A patent/CA2740262C/en not_active Expired - Fee Related
- 2009-11-10 DK DK09752080.3T patent/DK2285784T3/da active
- 2009-11-10 CN CN200980144578.1A patent/CN102209713B/zh not_active Expired - Fee Related
- 2009-11-10 RS RS20120326A patent/RS52381B/en unknown
- 2009-11-10 WO PCT/US2009/063816 patent/WO2010056644A1/en active Application Filing
- 2009-11-10 ES ES09752080T patent/ES2389694T3/es active Active
- 2009-11-10 PT PT09752080T patent/PT2285784E/pt unknown
- 2009-11-10 JP JP2011536412A patent/JP5087171B2/ja not_active Expired - Fee Related
- 2009-11-11 TW TW098138260A patent/TWI481605B/zh not_active IP Right Cessation
- 2009-11-11 AR ARP090104372A patent/AR074325A1/es not_active Application Discontinuation
- 2009-11-11 US US12/616,201 patent/US8063053B2/en not_active Expired - Fee Related
- 2009-11-11 SA SA109300673A patent/SA109300673B1/ar unknown
-
2011
- 2011-04-07 IL IL212213A patent/IL212213A0/en not_active IP Right Cessation
- 2011-04-22 TN TN2011000203A patent/TN2011000203A1/fr unknown
- 2011-05-05 ZA ZA2011/03283A patent/ZA201103283B/en unknown
- 2011-05-10 CL CL2011001050A patent/CL2011001050A1/es unknown
- 2011-05-10 NI NI201100093A patent/NI201100093A/es unknown
- 2011-05-10 DO DO2011000130A patent/DOP2011000130A/es unknown
- 2011-05-11 CU CU2011000101A patent/CU24020B1/es active IP Right Grant
- 2011-05-11 CR CR20110247A patent/CR20110247A/es unknown
- 2011-05-11 SV SV2011003902A patent/SV2011003902A/es unknown
- 2011-05-11 MA MA33836A patent/MA32788B1/fr unknown
- 2011-05-11 EC EC2011011045A patent/ECSP11011045A/es unknown
- 2011-05-12 CO CO11058600A patent/CO6440548A2/es active IP Right Grant
-
2012
- 2012-08-13 CY CY20121100721T patent/CY1113025T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000130A (es) | 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 | |
| CO6331428A2 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| DOP2010000277A (es) | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 | |
| CR20130308A (es) | Compuestos y su uso como inhibidores de bace | |
| BR9707636A (pt) | Composto composição farmacêutica uso de um composto e processos para preparar composto e para tratar um distúrbio ou doença de um organismo animal vivo | |
| MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
| JP2012508275A5 (en:Method) | ||
| UY32241A (es) | Derivados de isoindol para el tratamiento de patologias relacionados con ab | |
| MX2009003183A (es) | Derivados de sulfonilpirazolincarboxamidina como antagonistas de 5-ht6. | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| NZ592571A (en) | Aryl piperazine and their use as alpha2c antagonists | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| GT200500297A (es) | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
| MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| SV2009002917A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| IL205045A0 (en) | Piperidinyl and piperazinyl modulators of ?? - secretase | |
| MX2011008850A (es) | Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3). | |
| IL189974A0 (en) | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | |
| JP2008519056A5 (en:Method) | ||
| MX2009012716A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. | |
| DE602005013080D1 (de) | Für prkcb1 kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung | |
| BRPI0909824A2 (pt) | 2-aminoquinolinas | |
| CL2008003138A1 (es) | Compuestos derivados de 6-(alcoxi o fenilalcoxi)-indan-1-alquil aminas aciladas; composicion farmaceutica; y uso para el tratamiento o prevencion de alteraciones melatoninergicos tales como depresion, alteraciones del sueno, diabetes, parkinson y enfermedad de alzheimer. |